Citations

Showing 10 of 108083 citations.

Putting words into action: Adopting vancomycin infusion reaction terminology
Lessard, Sarah , Patel, Lydia, Fung, Brian , Rivera, Christina G. , Zimmermann, Elizabeth, Rivera, Christina G , Zimmermann, Elizabeth

Mayo Clinic

American Journal of Health-System Pharmacy | November 15, 2022 | Volume: 80 | Issue: 4 | Pages: 175-176

10.1093/ajhp/zxac345 | PMID 36377862 Get It

TaxiBGC: a Taxonomy-Guided Approach for Profiling Experimentally Characterized Microbial Biosynthetic Gene Clusters and Secondary Metabolite Production Potential in Metagenomes
Gupta, Vinod K. , Bakshi, Utpal , Chang, Daniel , Lee, Aileen R. , Chandrasekaran, Sriram , Sung, Jaeyun , Sung, Jaeyun , Davis, John M., Jin, Yong‐Su , Freeman, Michael F.

Mayo Clinic

mSystems | November 15, 2022 | Volume: 7 | Issue: 6 | Pages: No page available

10.1128/msystems.00925-22 | PMID 36378489 Get It

Currently available bioinformatics tools to identify BGCs from metagenomic sequencing data are limited in their predictive capability or ease of use to even computationally oriented researchers. We present an automated computational pipeline called TaxiBGC, which predicts experimentally characterized BGCs (and infers their known SMs) in shotgun metagenomes by first considering the microbial species source.
Racial disparities in pediatric malignant glioma management: current state of affairs in the United States
D’Amico, Randy S. , Lu, Victor M. , Niazi, Toba N., Nesvick, Cody L.

Mayo Clinic

No container title available | November 15, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.52843/cassyni.8w5bcv Get It

On this episode of Tumor Talk, Dr. Randy D'Amico and Dr. Jason Sheehan discuss the racial disparities in pediatric malignant glioma management with University of Miami/Jackson Health System Neurosurgical Resident, Dr. Victor Lu, Pediatric Neurosurgeon and Medical Director of Neuro-Oncology Surgical Services at Nicklaus Children's Hospital, Dr. Toba Niazi, and Neurologic Surgery Residency at the Mayo Clinic School of Graduate Medical Education, Dr. Cody Nesvick.
Commentary: Surgical Management of Peripheral Nerve Pathology in Patients With Neurofibromatosis Type 2
Bhandarkar, Archis R. , Spinner, Robert J.

Mayo Clinic

Neurosurgery | November 15, 2022 | Volume: 92 | Issue: 2 | Pages: e15-e16

10.1227/neu.0000000000002241 | PMID 36377908 Get It

Commentary: Precuneal Interhemispheric, Transtentorial Approach to a Dorsal Pontine Cavernous Malformation: 2-Dimensional Operative Video
Bauman, Megan M. J. , Bocanegra‐Becerra, Jhon E. , Patra, Devi Prasad, Meyer, Jenna H., Meyer, Fredric B. , Sands, Kara, Patra, Devi P. , Sands, Kara A, Bauman, Megan , Bendok, Bernard R.

Mayo Clinic

Operative Neurosurgery | November 15, 2022 | Volume: 23 | Issue: 6 | Pages: e403-e404

10.1227/ons.0000000000000467 | PMID 36377912 Get It

Commentary: Endoscopic Endonasal Removal of a Laterally Extended Pituitary Adenoma Using Steerable Forceps: 2-Dimensional Operative Video
Bauman, Megan M. J. , Graves, Jeffrey P., Patra, Devi Prasad, Marino, Michael J. , Miglani, Amar , Bendok, Bernard R. , Patra, Devi, Bauman, Megan

Mayo Clinic

Operative Neurosurgery | November 15, 2022 | Volume: 23 | Issue: 6 | Pages: e392-e393

10.1227/ons.0000000000000432 | PMID 36377910 Get It

Abstract B005: Polycyclic aromatic hydrocarbons and pancreatic cancer: An analysis of blood biomarker PheT as an exposure identifier
Nguyen, Sierra, Oberg, Ann L. , Peterson, Gloria, Hecht, Steven A., Carlson, Heather, Yoder, Andrea R. , Bamlet, William R. , Hecht, Steven, Jansen, Rick J.

Mayo Clinic

Cancer Research | November 15, 2022 | Volume: 82 | Issue: 22_Supplement | Pages: B005-B005

10.1158/1538-7445.panca22-b005 Get It

Abstract Exposure to polycyclic aromatic hydrocarbons (PAHs), a byproduct of incomplete combustion, and its effects on the development of cancer needs further evaluation. Recent studies have analyzed the relationship between PAHs and tobacco or dietary intake in the form of processed foods and smoked/well-done meats. This study aims to assess the association of a blood biomarker and metabolite of PAHs, r-1-,t-2,3,c-4-tetrahydroxy-1,2,3,4-tetrahydrophenanthrene (PheT), selected metabolism SNPs, and pancreatic cancer. Demographics, food-frequency data, SNPs, treatment history and levels of PheT in plasma were collected from 400 participants (202 cases and 198 control) and evaluated based on pancreatic adenocarcinoma diagnosis. A two-stage analysis was completed to identify 1) SNPs that were significantly associated with pancreatic cancer and 2) Dietary intake and PheT variables significantly associated with pancreatic cancer. A univariate analysis for variables with OR≠1 and p-value < 0.05 suggests significant relationship with pancreatic cancer and were carried forward to a multiple regression model for either food items or SNPs. Backward stepwise selection was used to eliminate non-significant variables. A collection of 5 SNPs were observed to form several of the most significant (adjusted p-value <0.05) interaction pairs across different SNP models. These were rs566979 (gene: CAT), rs28540420 (gene: PTGER4), rs12029406 (gene: none), rs730368 (gene: PTGER4), and rs3181077 (gene: CCR1). A final multiple regression model combined the significant food items and SNPs. Final significant factors associated with pancreatic cancer after backward selection included: Type 2 Diabetes [7.66 (3.46, 17.76)], corrected percent recovered version of the PAH (cPheT) [1.03 (1.02, 1.05)], very well done red meat [0.90 (0.84, 0.96)], recessive(rs12203582) [3.58 (1.50, 8.83)], recessive(rs56679) [0.25 (0.06, 0.80)], overdominant(rs3784605) [3.42 (1.81, 6.66)], overdominant(rs721430) [0.42 (0.21, 0.83)]. Of note by design, the level of smoking did not differ between our cases and controls. This study provides evidence that a metabolite PheT could be a biomarker of pancreatic cancer independent of dietary intake, smoking, and select metabolism SNPs. Citation Format: Sierra Nguyen, Heather Carlson, Andrea Yoder, William R. Bamlet, Ann L. Oberg, Gloria M. Peterson, Steven Hecht, Rick Jansen. Polycyclic aromatic hydrocarbons and pancreatic cancer: An analysis of blood biomarker PheT as an exposure identifier [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer; 2022 Sep 13-16; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2022;82(22 Suppl):Abstract nr B005.
Abstract A033: Gene-specific risk of syndrome-associated cancers in first-degree relatives of pancreatic cancer patients with pathogenic/likely pathogenic variants
Meyer, Margaret, Kemppainen, Jennnifer, Horibe, Masayasu, Chandra, Shruti , Majumder, Shounak, Petersen, Gloria M. , Chen, Xuan , Rabe, Kari G. , Meyer, Margaret, Kemppainen, Jennifer L., Horibe, Masayasu

Mayo Clinic

Cancer Research | November 15, 2022 | Volume: 82 | Issue: 22_Supplement | Pages: A033-A033

10.1158/1538-7445.panca22-a033 Get It

Abstract Increased pancreatic cancer (PC) risk in first-degree relatives (FDRs) of PC patients with germline pathogenic/likely pathogenic variants (PLPV) is a motivator for cascade genetic testing. To date, unbiased FDR risk estimates for gene-specific risks of genetic cancer syndrome-associated cancers are unknown. These estimates would enhance genetic counseling of at-risk FDRs in families where the PC proband has been found to carry a PLPV. Study Aim: To objectively quantify gene-specific risks of six relevant cancers among FDRs of PC patients with germline PLPV in ATM, BRCA1, BRCA2, CDKN2A, MLH1, MSH2, MSH6, PALB2, and PMS2. Methods: In the prospective, clinic-based Mayo Clinic Biospecimen Resource for Pancreas Research registry, 4,562 PC patients had previously undergone germline genetic testing for pancreatic cancer-associated genes through either research studies or clinical testing. Of these, 234 PC probands were found to carry PLPV among 9 genes of interest and had provided detailed demographic and cancer data on their FDRs by questionnaire. We focused on six cancer types (ovary, breast, uterus, pancreas, colon, and malignant melanoma) in FDRs as reported by the probands. Standardized incidence ratios estimated risk by gene of six cancers among FDRs of PC patients carrying PLPV. Results: 1,670 FDRs (mean age 58.1+17.8SD; 48.9% female) were included in the study. We found significantly increased risk of ovarian cancer in female FDRs of PC probands who carry PLPV in BRCA1 (SIR 9.49, 95%CI:3.06-22.14) or BRCA2 (3.72, 95%CI:1.36-8.11), and breast cancer risks were higher with BRCA2 (2.62, 95%CI:1.89-3.54). Uterine cancer risk was increased in FDRs of PC probands who carry PLPV for Lynch Syndrome mismatch repair (MMR) (6.53, 95%CI:2.81-12.86). PC risk was also increased (ATM 4.53, 95% CI:2.69-7.16; BRCA2 3.45, 95%CI:1.72-6.17; CDKN2A 7.38, 95%CI:3.18-14.54; PALB2 5.39, 95%CI:1.45-13.79). Increased colon cancer risk was observed in FDRs of probands who carried MMR PLPV (5.83, 95%CI:3.70-8.75), while melanoma risk was elevated for FDRs of probands with CDKN2A PLPV (7.47, 95%CI:3.97-12.77). Conclusion: PLPV in nine syndrome-associated genes in PC probands are associated with increased risk of six cancers in FDRs in PC families. The findings underscore the importance of risk estimation of various other cancers in PC families for screening, early detection, and intervention. The gene-specific quantified cancer risks for FDRs of PC patients with syndrome-associated germline PLPV can inform counseling regarding extra-PC risks when considering cascade genetic testing. Citation Format: Xuan Chen, Kari Rabe, Margaret Meyer, Jennnifer Kemppainen, Masayasu Horibe, Shruti Chandra, Shounak Majumder, Gloria Petersen. Gene-specific risk of syndrome-associated cancers in first-degree relatives of pancreatic cancer patients with pathogenic/likely pathogenic variants [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer; 2022 Sep 13-16; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2022;82(22 Suppl):Abstract nr A033.
Abstract A002: Purity Independent Subtyping of Tumor (PurIST): Real-world data validation of a pancreatic ductal adenocarcinoma (PDAC) gene expression classifier and its prognostic implications
Wang, Yun E., Mayhew, Gregory M. , Kang, Hyunseok P. , Milburn, Michael V., Wenric, Stéphane , Davison, James M. , Beebe, Kirk D. , Chung, Vincent , Bekaii‐Saab, Tanios , Perou, Charles M.

Mayo Clinic

Cancer Research | November 15, 2022 | Volume: 82 | Issue: 22_Supplement | Pages: A002-A002

10.1158/1538-7445.panca22-a002 Get It

Abstract Background: PDAC is a highly morbid disease with no validated biomarkers for first-line (1L) treatment selection. The PurIST single-sample molecular subtyping gene signature, initially described by Rashid et al. (Clin. Cancer Res., 2020), classifies PDAC tumors as basal or classical. Prior work showed that these subtypes are associated with prognosis and that basal subtype patients have significantly lower objective response rate to FOLFIRINOX (FFX) compared to classical subtype patients. This suggests potential implications for treatment with FFX versus gemcitabine and nab-paclitaxel (GnP). Here, we retrospectively demonstrate the clinical validity of PurIST implemented as a laboratory developed test (LDT) on the Tempus Labs sequencing platform using a real-world dataset of advanced PDAC patients. Methods: De-identified PDAC patients were selected from the Tempus Oncology Data Ecosystem under an IRB-approved protocol according to the following inclusion criteria: no systemic treatment, surgically unresectable/metastatic, available RNA-sequencing data from primary or metastatic tissue, and FFX or GnP as 1L systemic therapy with available outcomes. Sequencing was performed by the CAP/CLIA validated Tempus xT assay. The PurIST model was applied to normalized RNA-sequence abundance files to compute a basal or classical subtype label. Predefined statistical analysis parameters included 12-month survival rate and median overall survival (OS) in FFX treated patients. OS was compared using Kaplan-Meier estimates, hazard ratios, and log-rank statistical tests. Results: 258 PDAC patients (64.9 +/- 9.9 yrs, 42% female), were identified for analysis with median OS of 11.7 months (95% CI: 10.6-13.7) and 12-month censorship rate of 12.8%. 151 patients were treated with FFX and 107 with GnP. 42 patients (28%) receiving FFX and 31 patients (29%) receiving GnP were classified as basal. Among FFX treated patients, median OS was 14.4 months (95% CI: 12.5-16.9) in classical patients vs. 9.4 months (95% CI: 8.3-14.5) in basal patients (HR = 1.72, 95% CI = 1.2-2.6, p=0.006). The 12-month survival rate was significantly lower in basal patients receiving FFX vs. classical patients (33.3% vs. 59.4%, p=0.011). In basal patients, no difference in OS was observed between FFX and GnP groups (p=0.6). Classical patients receiving FFX had a 14.4 months median OS vs. 10.8 months for patients receiving GnP (p=0.046). Conclusions: In this real-world cohort, we validate the association between PurIST subtypes and PDAC patient survival when administered FFX or GnP. Among FFX-treated patients, classical patients had significantly better outcomes compared to basal patients. Moreover, classical patients appeared to have improved outcomes with FFX vs. GnP. These findings represent underlying biological PDAC differences and demonstrate the clinical validity of PurIST as a prognostic marker in PDAC patients when performed as an LDT on the Tempus xT platform. Ongoing evaluation of PurIST performance will be continuously monitored through the Tempus Oncology Data ecosystem. Citation Format: Stephane Wenric, James M. Davison, Yun E. Wang, Gregory M. Mayhew, Kirk Beebe, Hyunseok P. Kang, Michael V. Milburn, Vincent Chung, Tanios Bekaii-Saab, Charles M. Perou. Purity Independent Subtyping of Tumor (PurIST): Real-world data validation of a pancreatic ductal adenocarcinoma (PDAC) gene expression classifier and its prognostic implications [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer; 2022 Sep 13-16; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2022;82(22 Suppl):Abstract nr A002.
Abstract A029: A randomized study of two Strategies of remote Genetic Education, Risk Assessment, and Testing (GENERATE) for family members of patients with pancreatic cancer
Rodriguez, Nicolette J. , Furniss, C. Sloane , Yurgelun, Matthew B. , Constantinou, Pamela E., Fortes, Ileana, Caruso, Alyson , Stopfer, Jill E. , Underhill‐Blazey, Meghan , Kenner, Barbara , Nelson, Scott H., Okumura, Sydney, Coffin, Tara B. , Ocean, Allyson J. , McAllister, Florencia , Lowy, Andrew M. , Lippman, Scott M. , Madlensky, Lisa , Petersen, Gloria M. , Ukaegbu, Chinedu I. , Schwartz, Alison , Nelson, Scott H., Zhou, Alicia Yiran , Uno, Hajime , Horiguchi, Miki , Klein, Alison P. , Garber, Judy E. , Goggins, Michael , Maitra, Anirban , Syngal, Sapna

Mayo Clinic

Cancer Research | November 15, 2022 | Volume: 82 | Issue: 22_Supplement | Pages: A029-A029

10.1158/1538-7445.panca22-a029 Get It

Abstract Background: Uptake of genetic testing for cancer susceptibility in family members of cancer patients is suboptimal. The GENetic Education, Risk Assessment, and TEsting (GENERATE) study evaluated two strategies of remote genetic education and testing in relatives of pancreatic ductal adenocarcinoma (PDAC) patients. Methods: Eligible participants had: a first-degree relative with PDAC or had a known pathogenic germline variant (PGV) in one of thirteen PDAC predisposition genes (APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, or TP53) and a first- or second-degree relative with PDAC. Participants were cluster-randomized by family into one of two arms. Arm 1 included an interactive telemedicine session with a genetic counselor, followed by genetic testing at a commercial laboratory. Arm 2 involved remote online genetic education and testing at the commercial laboratory without the interactive session. The primary outcome was uptake of genetic testing across study arms, which was compared by permutation tests and mixed-effects logistic regression models. Results: Between 5/8/2019 and 6/1/2021, 424 families were randomized, including 601 participants (n=296 Arm 1; n=305 Arm 2). The uptake of genetic testing was 87% (257/296) in Arm 1 and 93% (284/305) in Arm 2 (p=0.014). Participants in Arm 1 were significantly less likely to obtain genetic testing compared to Arm 2 (Adjusted ratio [Arm1/Arm2] 0.90, 95% confidence interval 0.78-0.98). BRCA2, ATM, CDKN2A and PALB2 were the most common PDAC susceptibility genes in which PGVs were identified. Conclusions: Remote methods of genetic education and testing are successful alternatives to traditional germline susceptibility testing. Citation Format: Nicolette J. Rodriguez, C. Sloane Furniss, Matthew B. Yurgelun, Chinedu Ukaegbu, Pamela E. Constantinou, Ileana Fortes, Alyson Caruso, Alison N. Schwartz, Jill E. Stopfer, Meghan Underhill-Blazey, Barbara Kenner, Scott H. Nelson, Sydney Okumura, Alicia Y. Zhou, Tara B. Coffin, Hajime Uno, Miki Horiguchi, Allyson J. Ocean, Florencia McAllister, Andrew M. Lowy, Scott M. Lippman, Alison P. Klein, Lisa Madlensky, Gloria M. Petersen, Judy E. Garber, Michael G. Goggins, Anirban Maitra, Sapna Syngal. A randomized study of two Strategies of remote Genetic Education, Risk Assessment, and Testing (GENERATE) for family members of patients with pancreatic cancer [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer; 2022 Sep 13-16; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2022;82(22 Suppl):Abstract nr A029.